Immune Pharmaceuticals Inc (IMNP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
1 BRIDGE PLAZA N, SUITE 270 FORT LEE, NJ 07024 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,508 | 2,734 | 6,776 | 76 | 22 | 111 | |||
| Cash and cash equivalents | 1,508 | 2,734 | 6,776 | 76 | 22 | 111 | |||
| Restricted cash and investments | 25 | ||||||||
| Other current assets | 230 | 215 | 255 | 348 | 231 | 353 | |||
| Total current assets: | 1,738 | 2,949 | 7,031 | 424 | 253 | 489 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 61 | 31 | 58 | 58 | 326 | ||||
| Intangible assets, net (including goodwill) | 5,363 | 6,247 | 6,477 | 6,707 | 6,963 | 2,729 | |||
| Intangible assets, net (excluding goodwill) | 5,363 | 6,247 | 6,477 | 6,707 | 6,963 | 2,729 | |||
| Regulated entity, other noncurrent assets | 200 | 300 | |||||||
| Other noncurrent assets | 100 | 100 | 100 | 121 | 122 | 340 | |||
| Other undisclosed noncurrent assets | 15,000 | 15,000 | 15,000 | 15,000 | 14,800 | 14,700 | |||
| Total noncurrent assets: | 20,524 | 21,378 | 21,577 | 21,886 | 22,143 | 18,395 | |||
| TOTAL ASSETS: | 22,262 | 24,327 | 28,608 | 22,310 | 22,396 | 18,884 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,497 | 5,950 | 5,689 | 8,242 | 6,801 | 5,944 | |||
| Accounts payable | 3,597 | 3,683 | 3,569 | 6,614 | 4,507 | 3,736 | |||
| Accrued liabilities | 1,900 | 2,267 | 2,120 | 1,628 | 2,294 | 2,208 | |||
| Debt | 6,864 | 3,172 | 3,296 | 5,519 | 7,381 | 1,952 | |||
| Due to related parties | 232 | 274 | 266 | 305 | 236 | 236 | |||
| Total current liabilities: | 12,593 | 9,396 | 9,251 | 14,066 | 14,418 | 8,132 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 870 | 1,434 | 1,457 | 1,738 | 2,176 | 1,059 | |||
| Long-term debt, excluding current maturities | 870 | 1,434 | 1,457 | 1,738 | 2,176 | 1,007 | |||
| Capital lease obligations | 52 | ||||||||
| Liabilities, other than long-term debt | 4,142 | 4,142 | 4,142 | 5,933 | 5,933 | 5,933 | |||
| Deferred tax liabilities, net | 4,142 | 4,142 | 4,142 | 5,933 | 5,933 | 5,933 | |||
| Total noncurrent liabilities: | 5,012 | 5,576 | 5,599 | 7,671 | 8,109 | 6,992 | |||
| Total liabilities: | 17,605 | 14,972 | 14,850 | 21,737 | 22,527 | 15,124 | |||
| Equity | |||||||||
| Equity, attributable to parent | 4,657 | 9,355 | 13,758 | 573 | (131) | 3,760 | |||
| Common stock | 4 | 3 | 2 | 1 | 1 | 1 | |||
| Additional paid in capital | 127,290 | 127,272 | 127,292 | 110,959 | 104,204 | 103,159 | |||
| Accumulated deficit | (122,637) | (117,920) | (113,536) | (110,387) | (104,336) | (99,400) | |||
| Total equity: | 4,657 | 9,355 | 13,758 | 573 | (131) | 3,760 | |||
| TOTAL LIABILITIES AND EQUITY: | 22,262 | 24,327 | 28,608 | 22,310 | 22,396 | 18,884 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | (100) | |||||||
| Operating expenses | (2,843) | (4,326) | (3,805) | (2,839) | (2,784) | (2,695) | ||
| Operating loss: | (2,843) | (4,326) | (3,805) | (2,839) | (2,784) | (2,695) | ||
| Nonoperating income (expense) | (1,874) | (58) | (293) | 278 | (10) | (3) | ||
| Other nonoperating income (expense) | (21) | (19) | (293) | 278 | (10) | (3) | ||
| Interest and debt expense | 181 | (65) | 982 | (3,585) | (2,142) | (1,055) | ||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (181) | 65 | (2,006) | 95 | ||||
| Loss from continuing operations before income taxes: | (4,717) | (4,384) | (5,122) | (6,051) | (4,936) | (3,753) | ||
| Other undisclosed income from continuing operations | 1,973 | |||||||
| Loss from continuing operations: | (4,717) | (4,384) | (3,149) | (6,051) | (4,936) | (3,753) | ||
| Loss before gain (loss) on sale of properties: | (4,717) | (4,384) | (3,149) | (6,051) | (4,936) | (3,753) | ||
| Net loss attributable to parent: | (4,717) | (4,384) | (3,149) | (6,051) | (4,936) | (3,753) | ||
| Other undisclosed net loss available to common stockholders, basic | (5,599) | (6,864) | ||||||
| Net loss available to common stockholders, diluted: | (10,316) | (4,384) | (10,013) | (6,051) | (4,936) | (3,753) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (4,717) | (4,384) | (3,149) | (6,051) | (4,936) | (3,753) | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,717) | (4,384) | (3,149) | (6,051) | (4,936) | (3,753) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.